Uricase and other novel agents for the management of patients with treatment-failure gout

Current Rheumatology Reports

Volumn 9, Issue 3, 2007, Pages 258-264

  Sundy, John S ^a   Hershfield, Michael S ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIINFLAMMATORY AGENT; FEBUXOSTAT; OXIPURINOL; PEGYLATED URICASE; PROBENECID; RASBURICASE; SUPEROXIDE DISMUTASE MACROGOL; UNCLASSIFIED DRUG; URATE; URATE OXIDASE; URICOZYME;

CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CONTROL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; GOUT; HUMAN; HYPERURICEMIA; LIVER FUNCTION TEST; NONHUMAN; PATIENT COMPLIANCE; RASH; REVIEW; SIDE EFFECT; TREATMENT FAILURE; URIC ACID BLOOD LEVEL;

ALLOPURINOL; GOUT; GOUT SUPPRESSANTS; HUMANS; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; THIAZOLES; TREATMENT FAILURE; URATE OXIDASE; URIC ACID;

EID: 34250727437     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-007-0041-y     Document Type: Review

References (38)

1. Becker MA, Jolly M: Clinical gout and pathogenesis of hyperuricemia. In Arthritis and Allied Conditions: A Textbook of Rheumatology, edn 15, vol. 2. Edited by Koopman WJ, Moreland LW. Philadelphia: Lippincott Williams and Wilkins; 2005:2303-2340.
2. Sarawate CA, Patel PA, Schumacher HR, et al.: Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006, 12:61-65.
3. Fang W, Zeng X, Li M, et al.: The management of gout at an academic healthcare center in Beijing: a physician survey. J Rheumatol 2006, 33:2041-2049.
4. Lawry GV 2nd, Fan PT, Bluestone R: Polyarticular versus monoarticular gout: a prospective, comparative analysis of clinical features. Medicine (Baltimore) 1988, 67:335-343.
5. Mikuls TR, Curtis JR, Allison JJ, et al.: Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system. J Rheumatol 2006, 33:562-566.
6. Mikuls TR, Farrar JT, Bilker WB, et al.: Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford) 2005, 44:1038-1042.
7. Mikuls TR, MacLean CH, Olivieri J, et al.: Quality of care indicators for gout management. Arthritis Rheum 2004, 50:937-943.
8. Mikuls TR, Saag KG: Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care? Curr Rheumatol Rep 2005, 7:242-249.
9. Neogi T, Hunter DJ, Chaisson CE, et al.: Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 2006, 33:104-109.
10. Pal B, Foxall M, Dysart T, et al.: How is gout managed in primary care? A review of current practice and proposed guidelines. Clin Rheumatol 2000, 19:21-25.
11. Sarawate CA, Brewer KK, Yang W, et al.: Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006, 81:925-934.
12. Smith P, Karlson N, Nair BR: Quality use of allopurinol in the elderly. J Qual Clin Pract 2000, 20:42-43.
13. •• Becker MA, Schumacher HR Jr, Wortmann RL, et al.: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353:2450-2461. In addition to characterizing the efficacy and safety of febuxostat, this clinical trial provides the most comprehensive published data set on the efficacy and safety of allopurinol in a randomized controlled trial.
14. Hande KR, Noone RM, Stone WJ: Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984, 76:47-56.
15. Dalbeth N, Kumar S, Stamp L, Gow P: Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006, 33:1646-1650.
16. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R: Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001, 60:981-983.
17. Hahn PC, Edwards NL: Management of hyperuricemia. In Arthritis and Allied Conditions: A Textbook of Rheumatology, edn 15, vol. 2. Edited by Koopman WJ, Moreland LW. Philadelphia: Lippincott Williams and Wilkins; 2005:2341-2355.
18. de Klerk E, van der Heijde D, Landewe R, et al.: Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003, 30:44-54.
19. Riedel AA, Nelson M, Joseph-Ridge N, et al.: Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004, 31:1575-1581.
20. Sundy JS, Becker MA, Schumacher HR, et al.: Multicenter longitudinal study of disease characteristics in patients with treatment failure gout. Ann Rheum Dis 2006, 65:272.
21. Sundy JS, Schumacher HR, Becker MA, et al.: Quality of life in patients with treatment failure gout. Ann Rheum Dis 2006, 65:271.
22. Becker MA, Kisicki J, Khosravan R, et al.: Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 2004, 23:1111-1116.
23. • Becker MA, Schumacher HR Jr, Wortmann RL, et al.: Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005, 52:916-923. Phase 2 clinical trial data using febuxostat in patients with gout.
24. Hoshide S, Takahashi Y, Ishikawa T, et al.: PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids 2004, 23:1117-1118.
25. Ames BN, Cathcart R, Schwiers E, Hochstein P: Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981, 78:6858-6862.
26. Wu X, Wakamiya M, Vaishnav S, et al.: Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sci U S A 1994, 91:742-746.
27. Kelly SJ, Delnomdedieu M, Oliverio MI, et al.: Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase. J Am Soc Nephrol 2001, 12:1001-1009.
28. Moolenburgh JD, Reinders MK, Jansen TL: Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. Clin Rheumatol 2006, 25:749-752.
29. Richette P, Bardin T: Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. Nat Clin Pract Rheumatol 2006, 2:338-342; quiz 343.
30. Rozenberg S, Roche B, Dorent R, et al.: Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases. Rev Rhum Engl Ed 1995, 62:392-394.
31. Vogt B: Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant 2005, 20:431-433.
32. Davis S, Park YK, Abuchowski A, Davis FF: Hypouricaemic effect of polyethyleneglycol modified urate oxidase. Lancet 1981, 2:281-283.
33. Chua CC, Greenberg ML, Viau AT, et al.: Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann Intern Med 1998, 109:114-117.
34. • Ganson NJ, Kelly SJ, Scarlett E, et al.: Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2006, 8:R12. Initial phase 1 study of PEG-uricase administered by subcutaneous injection. Describes rapid and sustained reduction in plasma urate levels.
35. •• Sundy JS, Ganson NJ, Kelly SJ, et al.: Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 2007, 56:1021-1028. Phase 1 study of intravenous administration of PEG-uricase also demonstrating rapid and sustained reduction of plasma urate levels. Supported rationale for phase 2 and phase 3 studies of intravenous PEG-uricase.
36. Sundy JS, Becker MA, Baraf HS, et al.: A phase 2 study of multiple doses of intravenous polyethylene glycol (PEG)-uricase in patients with hyperuricemia and refractory gout [abstract]. Arthritis Rheum 2005, 52:S679.
37. Baraf HS, Kim S, Matsumoto AK, Maroli AN: Resolution of tophi with intravenous PEG-uricase in refractory gout [abstract]. Arthritis Rheum 2005, 52:S105.
38. Perez-Ruiz F, Calabozo M, Pijoan JI, et al.: Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002, 47:356-360.